精选行业洞察美国 FDAT1072
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
🤖 AI 摘要
The U.S. Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
分析模型：rule-based-v3 · 07-09 06:59
评分详情
综合分 72/100
信源权威
95
影响范围
75
时效性
50
合规紧急
40
行业关注
75
FDA Press Releases (新闻发布)
操作：